Atopic Dermatitis

A new gene expression profiling (GEP) test may transform how clinicians select systemic treatments for moderate to severe atopic dermatitis (AD).

The combination of rapid onset and durable response positions zumilokibart as a potentially attractive first-line biologic option.

At AAD 2026, Diego Ruiz Dasilva, MD, makes the case that the black box warning on JAK inhibitors shouldn't deter appropriate prescribing.

Mark Jackson, MD, of Evommune, provides a therapeutic update on the investigational atopic dermatitis drug, citing strong efficacy and safety after just 2 doses, with phase 2b research on the way.

The ongoing phase 2b BROADEN2 study will evaluate KT-621 across 3 dose levels in 200 patients over 16 weeks, with results expected to guide phase 3 dose selection.

The combination therapy SHORE trial produced the highest response rates of the 3 studies, with EASI-75 approaching 48% in the Q4W arm.

LEO Pharma presented 3 AAD posters on the efficacy of tralokinumab in various AD subgroups across the 12-month TRACE program.

Eight in ten ADlong patients achieved clinical response without steroid rescue, strengthening the case for lebrikizumab as a standalone, long-term management option.

At AAD 2026, Christopher Bunick, MD, PhD, and Patrick Burnett, MD, PhD, discuss late-breaking data of roflumilast cream's improvements in infants with AD.

Late-breaking phase 2 findings presented at AAD show nemolizumab achieved high EASI-90 rates and rapid itch relief in pediatric patients with atopic dermatitis.

With 80% of trial participants being children, this analysis provides some of the most robust early-response data available for a non-steroidal topical in pediatric AD.

Targeted therapies are increasingly used earlier in treatment rather than being reserved for severe or refractory cases.

Phase 2 APEX part A data showed zumilokibart maintained EASI-75 responses in 75–85% of week 16 responders at 1 year across quarterly and biannual dosing regimens.

New data show that nearly 40% of eczema patients face insurance-related barriers, delaying or preventing access to prescribed therapies.

Meta-analysis finds sexual dysfunction common in asthma and AD, with rates hitting 54% in asthma, prompting better screening.

Positive phase 3 findings from ADorable-1 suggest lebrikizumab could expand biologic treatment options for younger patients with atopic dermatitis (AD).

Mark Lebwohl, MD, reviews how the AdvanceAD-Tx 487-GEP test identifies which patients are likely to need a JAK inhibitor rather than a biologic.

Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed clinical cases highlighting the distinct roles of topical ruxolitinib, tapinarof, and roflumilast in managing itch, inflammation, and long-term disease control in atopic dermatitis.

Mark Lebwohl, MD, discusses how the 487-GEP test may help clinicians identify the most appropriate systemic therapy for patients with AD earlier in the treatment journey.

Omar Noor, MD, shares pearls on type 2 inflammation, including dupilumab insights for atopic dermatitis, prurigo nodularis, and CSU at Horizons in Advanced Practice.

Rocatinlimab had met primary end points in large phase 3 trials and was previously expected to move toward regulatory submission in 2026.

The double-blind, randomized, placebo-controlled ARQ-234-131 study will assess safety, tolerability, pharmacokinetics, and early signs of clinical activity.

At Winter Clinical Miami 2026, April Armstrong, MD, MPH, spotlights new pediatric topicals and JAK safety insights, plus targeted options for head-and-neck atopic dermatitis.

Mark Lebwohl, MD, shares his Winter Clinical Miami 2026 highlights, including oral psoriasis peptides, atopic dermatitis advances, GLP-1 combos, and more.

More than 57% of patients with ACD reported moderate to severe quality-of-life impairment, with symptoms and embarrassment among the most affected areas.